News
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics' proprietary OGAP® ...
Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every ...
During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...
Bristol-Myers Squibb terminated a real-world, non-interventional study on Ozanimod, targeting moderate-to-severe ulcerative ...
BIO, a key biotech lobby group, labels RFK Jr. a public health threat amid vaccine skepticism. Read more here.
During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.
Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity ...
The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...
19h
Zacks Investment Research on MSNVEEV Integrates GenAI in Vault Platform to Drive Workflow AutomationVeeva Systems VEEV is expanding its capabilities by introducing Veeva AI, a generative AI layer built into its core Vault ...
On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results